SCHEMBL2762697

SCHEMBL2762697

O=S(=O)(Nc1nc(-c2sccc2Cl)cs1)c1cc(Cl)c(Cl)cc1Cl

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.78
USP2 O75604 2/20 0.78
MAPT P10636 2/20 0.78
CYP1A2 P05177 1/20 0.78
CYP3A4 P08684 1/20 0.78
CYP2D6 P10635 1/20 0.78
CYP2C9 P11712 1/20 0.78
CYP2C19 P33261 1/20 0.78
RECQL P46063 1/20 0.78
NPSR1 Q6W5P4 1/20 0.78
HSD11B1 P28845 1/20 0.67
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
KDM1A O60341 11/20 0.49
MAOA P21397 5/20 0.49
ABL1 P00519 1/20 0.46
ESR2 Q92731 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762538 0.88 POLB (1.00) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762552 0.84 POLB (0.73) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762799 0.84 POLB (0.72) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762583 0.82 POLB (0.67) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762613 0.81 POLB (0.65) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762496 0.81 HSD11B1 (1.00) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL5831190 0.79 USP2 (0.51) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762574 0.79 POLB (0.65) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL5831578 0.79 USP2 (0.50) POLBUSP2MAPTCYP1A2CYP3A4
SCHEMBL2762837 0.78 HSD11B1 (0.64) POLBUSP2MAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP claimed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 POLB 500/4885USP2 2823/4885MAPT 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.